Prothena Corporation plc: Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
Prothena (NASDAQ:PRTA) reported Q2 2026 results and business updates. Quarter-end cash and restricted cash were $289.1M, with updated 2026 cash guidance to about $259M (midpoint). Q2 net loss was $18.6M. The company cited Roche Phase 2b PADOVA prasinezumab data in The Lancet and ongoing Phase 3 and other partner trials.
How this was made
The 30-second read
Why it matters
The update combines (1) a balance-sheet/cash runway signal via revised year-end cash expectations and (2) a new external clinical datapoint via Roche’s Lancet publication of PADOVA Phase 2b results, which can influence perceived probability-weighted milestones and royalties.
Market read
Traders may reprice PRTA on updated cash guidance and on the market’s interpretation of newly published Phase 2b Parkinson’s signals that feed into Phase 3 expectations and milestone probability.
What to watch
Cash burn and small reported revenue mean the stock may remain highly sensitive to financing risk and to the pace of milestone triggers, not just early signals.
Background
Prothena is a late-stage clinical biotech with partnered programs in Parkinson’s (prasinezumab with Roche), ATTR amyloidosis (coramitug with Novo Nordisk), and Alzheimer’s (moponetug with BMS), plus proprietary CYTOPE technology.
Ticker impact
Prothena reported Q2 2026 results, updated year-end cash guidance to about $259M, and highlighted Roche Phase 2b PADOVA prasinezumab data.
Near-term bias modestly positive, with follow-through tied to how investors interpret PADOVA signals and the implied probability of Phase 3 success.
The article provides concrete balance-sheet guidance (cash target) and a specific new external catalyst (Lancet publication of PADOVA Phase 2b results), both of which can affect valuation and risk appetite for a late-stage biotech.
Market effects
Reinforces investor focus on alpha-synuclein and tau-targeting antibody platforms and on disease-modifying claims in neurodegeneration.
No clear regional transmission beyond US biotech sentiment.
Partner-driven global trials (Roche, Novo Nordisk, BMS) keep attention on European and global pharma collaboration pipelines.
Counterpoint
PADOVA is Phase 2b and exploratory; investors may discount the Lancet publication until Phase 3 PARAISO shows clear clinical benefit.
Key entities
- companyProthena Corporation plc
Reports Q2 2026 financial results, updates cash guidance, and highlights partner clinical progress across multiple neurodegenerative programs.
- partnerRoche
Published Phase 2b PADOVA results in The Lancet for prasinezumab in early Parkinson’s disease; running Phase 3 PARAISO.
- partnerNovo Nordisk
Conducts Phase 3 CLEOPATTRA for coramitug in ATTR amyloidosis with cardiomyopathy; also acquiring Prothena’s ATTR business/pipeline.
- partnerBristol Myers Squibb
Conducts Phase 2 TargetTau-1 for moponetug in early Alzheimer’s disease; decision on advancing expected by YE 2026.
